Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 71 (3), 273-282

Class I Transactivator, NLRC5: A Central Player in the MHC Class I Pathway and Cancer Immune Surveillance

Affiliations
Review

Class I Transactivator, NLRC5: A Central Player in the MHC Class I Pathway and Cancer Immune Surveillance

Saptha Vijayan et al. Immunogenetics.

Abstract

Major histocompatibility complex (MHC) class I and class II molecules play critical roles in the activation of the adaptive immune system by presenting antigens to CD8+ and CD4+ T cells, respectively. Although it has been well known that CIITA (MHC class II transactivator), an NLR (nucleotide-binding domain, leucine-rich-repeat containing) protein, as a master regulator of MHC class II gene expression, the mechanism of MHC class I gene transactivation was unclear. Recently, another NLR protein, NLRC5 (NLR family, CARD domain-containing 5), was identified as an MHC class I transactivator (CITA). NLRC5 is a critical regulator for the transcriptional activation of MHC class I genes and other genes involved in the MHC class I antigen presentation pathway. CITA/NLRC5 plays a crucial role in human cancer immunity through the recruitment and activation of tumor killing CD8+ T cells. Here, we discuss the molecular function and mechanism of CITA/NLRC5 in the MHC class I pathway and its role in cancer.

Keywords: CIITA; CITA/NLRC5; Cancer; MHC class I; NLR proteins.

Similar articles

See all similar articles

Cited by 5 articles

References

    1. Cell. 1994 Jan 28;76(2):287-99 - PubMed

References

    1. Cell. 1993 Oct 8;75(1):135-46 - PubMed

References

    1. Cell. 2002 Apr;109 Suppl:S21-33 - PubMed

References

    1. Proc Natl Acad Sci U S A. 1983 Apr;80(7):1982-6 - PubMed

References

    1. J Immunol. 2010 Feb 15;184(4):1990-2000 - PubMed

References

    1. Front Immunol. 2011 Oct 04;2:48 - PubMed

References

    1. Biofactors. 2016 Jul 8;42(4):349-57 - PubMed

References

    1. Cell. 2014 Jul 31;158(3):506-21 - PubMed

References

    1. J Exp Med. 2000 Mar 20;191(6):961-76 - PubMed

References

    1. Immunity. 1999 Feb;10(2):163-71 - PubMed

References

    1. J Biol Chem. 2012 Jul 13;287(29):24294-303 - PubMed

References

    1. J Cell Biol. 2015 Dec 7;211(5):1025-40 - PubMed

References

    1. Science. 2011 Mar 25;331(6024):1565-70 - PubMed

References

    1. J Immunol. 2010 Aug 1;185(3):1681-91 - PubMed

References

    1. Genes Dev. 2000 May 1;14(9):1156-66 - PubMed

References

    1. Int J Cancer. 2010 Jul 15;127(2):249-56 - PubMed

References

    1. Oncoimmunology. 2018 Mar 26;7(7):e1445453 - PubMed

References

    1. J Immunol. 2012 May 15;188(10):4951-8 - PubMed

References

    1. Mol Cell Biol. 2000 Nov;20(22):8489-98 - PubMed

References

    1. Immunity. 1997 May;6(5):601-11 - PubMed

References

    1. Biochemistry. 2014 May 20;53(19):3106-17 - PubMed

References

    1. Biochem Biophys Res Commun. 2012 Feb 24;418(4):786-91 - PubMed

References

    1. J Immunol. 2001 Oct 1;167(7):3626-34 - PubMed

References

    1. Mol Cell Biol. 2000 Aug;20(16):6051-61 - PubMed

References

    1. J Biol Chem. 2010 Aug 20;285(34):26223-32 - PubMed

References

    1. Cell. 1988 Jun 17;53(6):897-906 - PubMed

References

    1. Genes Dev. 1995 May 1;9(9):1021-32 - PubMed

References

    1. J Immunol. 1999 Aug 1;163(3):1428-34 - PubMed

References

    1. J Immunol. 2012 Apr 15;188(8):3820-8 - PubMed

References

    1. Int J Cancer. 2003 Mar 1;103(6):759-67 - PubMed

References

    1. Microbes Infect. 2012 Jun;14(6):477-84 - PubMed

References

    1. J Virol. 2015 Aug;89(15):7636-45 - PubMed

References

    1. J Cell Biol. 2015 Dec 7;211(5):941-3 - PubMed

References

    1. Proc Natl Acad Sci U S A. 2016 May 24;113(21):5999-6004 - PubMed

References

    1. Immunity. 1997 May;6(5):591-600 - PubMed

References

    1. J Immunol. 2011 Jan 15;186(2):994-1000 - PubMed

References

    1. J Immunol. 1998 Sep 1;161(5):2276-83 - PubMed

References

    1. J Exp Med. 1994 Oct 1;180(4):1367-74 - PubMed

References

    1. J Immunol. 2011 Feb 1;186(3):1333-7 - PubMed

References

    1. EMBO J. 1997 Mar 3;16(5):1045-55 - PubMed

References

    1. PLoS Genet. 2015 Mar 26;11(3):e1005088 - PubMed

References

    1. Nat Genet. 1998 Nov;20(3):273-7 - PubMed

References

    1. J Biol Chem. 2007 Sep 7;282(36):26178-84 - PubMed

References

    1. Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13794-9 - PubMed

References

    1. J Immunol. 1999 Sep 1;163(5):2425-31 - PubMed

References

    1. Immunity. 1998 Oct;9(4):531-41 - PubMed

References

    1. Immunity. 1999 Feb;10(2):153-62 - PubMed

References

    1. J Immunol. 2001 Nov 1;167(9):5175-84 - PubMed

References

    1. J Biol Chem. 2001 Jun 1;276(22):19089-93 - PubMed

References

    1. Eur J Immunol. 2015 Mar;45(3):758-72 - PubMed

References

    1. J Virol. 2017 Aug 10;91(17): - PubMed

References

    1. J Immunol. 2012 Jul 15;189(2):516-20 - PubMed

References

    1. Cancer Immunol Immunother. 2002 Sep;51(7):389-96 - PubMed

References

    1. Oncoimmunology. 2016 Mar 28;5(6):e1151593 - PubMed

References

    1. Annu Rev Immunol. 2001;19:331-73 - PubMed

References

    1. Science. 1999 Aug 27;285(5432):1402-5 - PubMed

References

    1. Immunity. 1996 Feb;4(2):167-78 - PubMed

References

    1. Nat Rev Genet. 2009 Aug;10(8):551-64 - PubMed

References

    1. Trends Cancer. 2017 Jan;3(1):28-38 - PubMed

References

    1. Immunity. 2018 Feb 20;48(2):271-285.e5 - PubMed

References

    1. Cell. 2010 Apr 30;141(3):483-96 - PubMed

References

    1. Cell Res. 2012 May;22(5):836-47 - PubMed

References

    1. J Immunol. 2012 May 15;188(10):4940-50 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

Feedback